医学
支气管扩张
共病
内科学
死亡率
危险系数
比例危险模型
队列
队列研究
重症监护医学
置信区间
肺
作者
Melissa J. McDonnell,Stefano Aliberti,Pieter Goeminne,Marcos I. Restrepo,Simon Finch,Alberto Pesci,Lieven Dupont,Thomas C. Fardon,Robert Wilson,Michael R. Loebinger,Dušan Škrbić,Dušanka Obradović,Anthony De Soyza,Chris Ward,John G. Laffey,Robert Rutherford,James D. Chalmers
标识
DOI:10.1016/s2213-2600(16)30320-4
摘要
Summary Background Patients with bronchiectasis often have concurrent comorbidities, but the nature, prevalence, and impact of these comorbidities on disease severity and outcome are poorly understood. We aimed to investigate comorbidities in patients with bronchiectasis and establish their prognostic value on disease severity and mortality rate. Methods An international multicentre cohort analysis of outpatients with bronchiectasis from four European centres followed up for 5 years was done for score derivation. Eligible patients were those with bronchiectasis confirmed by high-resolution CT and a compatible clinical history. Comorbidity diagnoses were based on standardised definitions and were obtained from full review of paper and electronic medical records, prescriptions, and investigator definitions. Weibull parametric survival analysis was used to model the prediction of the 5 year mortality rate to construct the Bronchiectasis Aetiology Comorbidity Index (BACI). We tested the BACI as a predictor of outcomes and explored whether the BACI added further prognostic information when used alongside the Bronchiectasis Severity Index (BSI). The BACI was validated in two independent international cohorts from the UK and Serbia. Findings Between June 1, 2006, and Nov 22, 2013, 1340 patients with bronchiectasis were screened and 986 patients were analysed. Patients had a median of four comorbidities (IQR 2–6; range 0–20). 13 comorbidities independently predicting mortality rate were integrated into the BACI. The overall hazard ratio for death conferred by a one-point increase in the BACI was 1·18 (95% CI 1·14–1·23; p vs BACI; p=0·008 for combined vs BSI). Interpretation Multimorbidity is frequent in bronchiectasis and can negatively affect survival. The BACI complements the BSI in the assessment and prediction of mortality and disease outcomes in patients with bronchiectasis. Funding European Bronchiectasis Network (EMBARC).
科研通智能强力驱动
Strongly Powered by AbleSci AI